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Bandrowski, A. E., J. R., Huguenard, and D. A. Prince. Baseline
glutamate levels affect group I and II mGluRs in layer V Pyramidal
neurons of rat sensorimotor cortex. J Neurophysiol 89: 1308–1316,
2003; 10.1152/jn.00644.2002. Possible functional roles for gluta-
mate that is detectable at low concentrations in the extracellular space
of intact brain and brain slices have not been explored. To determine
whether this endogenous glutamate acts on metabotropic glutamate
receptors (mGluRs), we obtained whole cell recordings from layer V
pyramidal neurons of rat sensorimotor cortical slices. Blockade of
mGluRs with ()--amino-4-carboxy--methyl-benzeacetic acid
(MCPG, a general mGluR antagonist) increased the mean amplitude
of spontaneous excitatory postsynaptic currents (sEPSCs), an effect
attributable to a selective increase in the occurrence of large amplitude
sEPSCs. 2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-
9-yl)propanoic acid (LY341495, a group II antagonist) increased, but
R()-1-amino-2,3-dihydro-1H-indene-1,5-dicarboxylic acid (AIDA)
and (RS)-hexyl-HIBO (group I antagonists) decreased sEPSC ampli-
tude, and (R,S)--cyclopropyl-4-phosphonophenylglycine (CPPG, a
group III antagonist) did not change it. The change in sEPSCs elicited
by MCPG, AIDA, and LY341495 was absent in tetrodotoxin, sug-
gesting that it was action potential-dependent. The increase in sEPSCs
persisted in GABA receptor antagonists, indicating that it was not
due to effects on inhibitory interneurons. AIDA and (S)-3,5-dihy-
droxyphenylglycine (DHPG, a group I agonist) elicited positive and
negative shifts in holding current, respectively. LY341495 and
(2S,2R,3R)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV, a group
II agonist) elicited negative and positive shifts in holding current,
respectively. The AIDA and LY341495 elicited currents persisted in
TTX. Finally, in current clamp, LY341495 depolarized cells by 2
mV and increased the number of action potentials to a given depo-
larizing current pulse. Thus ambient levels of glutamate tonically
activate mGluRs and regulate cortical excitability.
INTRODUCTION
Glutamate is rapidly released from presynaptic terminals and
exerts its action on both ionotropic and metabotropic glutamate
receptors, whose function has been carefully deﬁned over
many years (Anwyl 1999; Collingridge and Lester 1989; Conn
and Pin 1997). In addition to this clearly demonstrated fast,
precise, and well-controlled release, there is abundant evidence
for a persistent low-level baseline concentration of glutamate
(0.5–2 M/L) in the brain in vivo (Meldrum 2000) and in
perfusate from unstimulated brain slices (Bianchi et al. 1999;
Kapetanovic et al. 1994). Although much is known about
glutamate released during synaptic transmission, the function
of steady-state low, but detectable, levels of glutamate in brain
remains relatively unexplored. Of particular interest in this
regard are metabotropic glutamate receptors (mGluRs), which
are coupled to G-proteins and have the ability to respond to low
concentrations of glutamate and modulate neuronal excitabil-
ity. These mGluRs, which are present in neocortex, are divided
into three major groups (I–III) on the basis of sequence ho-
mology and agonist afﬁnity, and they have a wide variety of
effects on neuronal communication and cellular excitability
(Anwyl 1999; Conn and Pin 1997; Meldrum 2000).
The present set of experiments was undertaken to determine
whether the baseline extracellular levels of glutamate in un-
stimulated neocortical slices, maintained under standard con-
ditions, might tonically activate mGluRs, and modulate spon-
taneous synaptic transmission. Portions of this work have
appeared in abstract form (Bandrowski et al. 2002).
METHODS
Brain slices were prepared from 13- to 20-day-old male and female
Sprague-Dawley rats. Animals were anesthetized with pentobarbital
(50 mg/kg), and their brains rapidly removed and placed in cold
sucrose-artiﬁcial cerebrospinal ﬂuid (ACSF) containing (in mM) 230
sucrose, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 0.5 CaCl2, 10 MgSO4,
and 10 glucose. This “cutting solution” was gassed with 95% O2-5%
CO2 and had a pH of 7.4. Coronal slices, 300 m in thickness, were
obtained from sensorimotor cortex (Zilles et al. 1980) between the
rostrocaudal landmarks of the anterior commissure and anterior hip-
pocampus, using a TPI vibratome (St. Louis, MO). Slices were
sequentially transferred into half sucrose-ACSF and then a standard
ACSF solution containing (in mM) 126 NaCl, 3 KCl, 1.25 NaH2PO4,
26 NaHCO3, 2 CaCl2, 2 MgSO4, and 10 glucose, that had an osmo-
larity of 298–302 mosmol and a pH of 7.4 when gassed with 95%
O2-5% CO2. After 1 h of equilibration at 32°C in an interface
holding chamber, temperature was allowed to return to 24°C, and
slices were transferred into a recording chamber where they were
minimally submerged, perfused with ACSF at a rate of 1.5–2 ml/min,
and maintained at 32°C. Typically, a light band 550–650 m from
the pial surface, corresponding to superﬁcial layer V, was identiﬁed
using the 2.5 objective of a Zeiss Axioskop (Carl Zeiss, Thornwood,
NY; Fig. 1A), and unless otherwise stated, recordings were made at
that location. Pyramidal cells were visualized with a 60 water-
immersion objective and identiﬁed as neurons with a single emerging
apical dendrite extending toward the pial surface (Fig. 1A). A few
such neurons were ﬁlled with biocytin (5% in the pipette solution),
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dal neurons (see processing methods in Horikawa and Armstrong
1988; Tseng et al. 1991).
Micropipettes for whole cell recording were pulled from borosili-
cate glass capillary tubes (ID: 0.84 mm, OD: 1.5 mm; WPI, Sarasota,
FL). Pipettes had tip diameters of 3 m and were ﬁlled with a
solution containing (in mM) 120 K
 gluconate, 10 KCl, 1 MgCl2,1
CaCl2, 10 ethylene glycol-bis(beta-aminoethylether)-N,N,N,N-tet-
raacetic acid (EGTA), 10 N-2 hydroxyethylpiperazine-N-2 ethane-
sulfonic acid (HEPES), 3 ATP, and 0.2 GTP, pH adjusted to pH 7.3
with KOH (1.0 M). Final osmolarity was 278–292 mosM, and DC
resistances were 1.5–3M . Series resistance (Ra) was monitored
every 1–5 min by applying brief voltage steps, and data from a given
cell were discarded if changes of 15% were detected during the
recording, or if values exceeded 17 M. Membrane currents and
potentials were monitored and stored on a PC using Clampex8 soft-
ware that interfaced with an Axopatch 200 ampliﬁer via the Digidata
1322A (Axon Instruments, Union City, CA). Clampex8 software was
programmed for stimulus delivery and data collection. The Axopatch
200 low-pass ﬁlter setting was 2 kHz, and the digitization rate was
5 kHz.
The following pharmacological agents were used: from Sigma/RBI
(St Louis, MO): R()-1-amino-2,3-dihydro-1H-indene-1,5-dicar-
boxylic acid (AIDA), 2-amino-5-phosphonovaleric acid (APV),
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), ()--amino-4-car-
boxy--methyl-benzeacetic acid (MCPG), 6-imino-3-(4-methoxy-
phenyl)-1(6H)-pyridazinebutanoic acid (SR 95531 hydrobromide or
gabazine); from Tocris (Ellisville, MO): 2S-2-amino-2-(1S,2S-2-
carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495),
(R,S)--cyclopropyl-4-phosphonophenylglycine (CPPG), (S)-3,5-di-
hydroxyphenylglycine (DHPG), (2S,2R,3R)-2-(2,3-dicarboxycy-
clopropyl)glycine (DCG IV); from Almone Labs: tetrodotoxin (TTX);
from CGP: CGP55845. (RS)-hexyl-HIBO (HIBO) was generously
donated by Dr. Ulf Madsen (compound 9 in Madsen et al. 2001).
These drugs were prepared as a concentrated stock solution in distilled
water, 0.1 M NaOH, solution (for MCPG, AIDA, HIBO, and
LY341495) or a 50% water-50% DMSO solution (for CNQX) and
diluted to ﬁnal concentration in ACSF. Drugs were stored in aliquots,
each of which was used only once to avoid loss of potency by the
freeze-thaw process. Drugs were either added to the bathing medium
(TTX, CNQX, APV, and gabazine) or applied locally to the slice
using a perfusion pipette placed 500 m from the recording pipette
(see also Sun et al. 2001). For local perfusion experiments, typically
two barrels of the pipette were ﬁlled, one with ACSF and the other
with the desired drug dissolved in ACSF. The area of the slice
containing the recorded cell was perfused with a stream of ACSF from
FIG.1 . A: images obtained from a 300-m-thick slice of sensorimotor cortex in the recording chamber (pial surface up). Top:
light band lies in upper layer V where recording electrodes (R) were placed. The local perfusion pipette (top right) was positioned
between layers I and III, in most experiments, so that ﬂow of perfusate would encompass the area of the recording pipette.
Calibration: 100 m. Bottom: image shows a typical superﬁcial layer V pyramidal cell soma and the proximal portion of the apical
dendrite extending toward the pial surface. Patch pipette from which recordings were made extends from left side. Calibration: 10
m. B:6so fcontinuous recording taken before drug application (pre-drug), at the 100-s marker in C, and in ()--amino-4-
carboxy--methyl-benzeacetic acid (MCPG, 0.2 mM), at the 300-s marker in C. Calibration: 40 pA, 50 ms. C: the peak amplitudes
of sEPSCs are plotted vs. time for the cell of B. Each point represents a spontaneous excitatory postsynaptic current (sEPSC). After
a 200-s pre-drug period, MCPG (0.2 mM) was superfused through the local perfusion system ( ). MCPG perfusion elicits a
reversible increase in large amplitude sEPSCs. D, top: MCPG perfusion (0.2 mM) increases mean sEPSC amplitude. Pre-Drug and
MCPG traces are averages of 48 and 54 type 1 (see METHODS) sEPSCs, respectively, obtained during 100-s periods. Calibration:
5 pA, 3 ms. Bottom: averaged sEPSCs of A are scaled to the same amplitude to show that events Pre-Drug and in MCPG do not
differ in rise times or decay time constants. E: a cumulative probability plot of sEPSC amplitudes from same cell. Median sEPSC
amplitude was larger in MCPG than control (K-S: P  0.01). F: graph of the mean frequency of sEPSCs in control (Pre) and
MCPG-containing solutions (MCPG) in 15 cells. All sEPSCs, all detectible events (see METHODS). Large sEPSCs: events with peak
amplitude 25 pA. *: P  0.05. ns: P  0.05.
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drug-containing ACSF from the second barrel for drug conditions.
The time to “wash on” the drug was typically 1–4 s, with some
variation due to placement of perfusion pipette.
Spontaneous excitatory postsynaptic currents (sEPSCs) were ana-
lyzed using detector software (Ulrich and Huguenard 1996). They had
average amplitudes of 9–27 pA, or about two to four times the
baseline noise level of 2–8 pA, and were divided by the software into
three types of events. Rise times, decay constants, amplitudes, and
time of occurrence were recorded for each event. Type 1 sEPSCs were
those that were not preceded or followed by another sEPSC within 20
ms, whereas types 2 and 3 sEPSCs were components of compound
sEPSCs in which one event was closely preceded or followed by
another. Holding potential (Vh), and membrane potential (Vm) mea-
surements were made using Clampﬁt Software (Axon Instruments) by
sampling a point every 10 s for the duration of data collection. Data
were pooled, and averages were determined using Microsoft Excel.
Graphs were generated using Microcal Origin software. Data are
presented as means 	 SE. Differences between means were evaluated
using the t-test for unpaired samples, or where appropriate, t-test for
paired samples. Statistical signiﬁcance was set at P  0.05.
RESULTS
We recorded from 104 visually identiﬁed superﬁcial layer V
pyramidal cells. Neurons included in the present data set had
an Ra  17 Ms (mean: 11.7 	 0.4 M), input resistance of
58.6 	 2.6 M, and resting membrane potential of 60.4 	
0.6 mV.
mGluR antagonism increases the amplitude of sEPSCs
To determine whether mGluRs were activated in unstimu-
lated slices of neocortex, we applied MCPG, a general antag-
onist of mGluRs, and monitored ongoing spontaneous synaptic
activity. sEPSCs had 10–90% rise times of 0.85 	 0.09 ms,
weighted decay time constants (D,W)o f4 . 6	 0.4 ms, and
were blocked by perfusion of APV/CNQX. Application of
MCPG to 15 cells gave rise to a signiﬁcant increase in sEPSC
amplitude of 18.0 	 5.6% (P  0.01) that lasted for the
duration of MCPG application (Fig. 1, B–E). This effect was
reversible, but variable, ranging froma0t o5 6 %increase.
These data suggest that mGluRs are tonically activated in
unstimulated neocortical slices, where they reduce sEPSC am-
plitudes in a signiﬁcant proportion of neurons. Analysis of rise
times and weighted decay time constants (D,W) in responsive
cells during MCPG application revealed no detectable change
from control. Figure 1D shows an average of all type 1 events
(see METHODS) obtained from one neuron during 100-s periods
before (48 events) and during MCPG perfusion (54 events).
Although sEPSCs increased in amplitude, no difference in rise
or decay times was present when mean sEPSCs were scaled to
the same amplitude (Fig. 1D). To determine whether all events
were larger or whether larger amplitude events were more
numerous, cumulative probability plots were generated. These
cumulative probability distributions revealed that MCPG
mainly increased the largest 40% of events (Fig. 1E). Anal-
ysis of the frequency of sEPSCs revealed no signiﬁcant change
between pre-drug and MCPG conditions (Fig. 1F, all sEPSCs).
However, when only events 25 pA were examined, a signif-
icant increase in sEPSC frequency was present in MCPG (P 
0.01; Fig. 1F, large sEPSCs). Thus MCPG selectively in-
creases the frequency of larger-amplitude events. To test for
nonspeciﬁc pH or osmolarity effects, we locally perfused
ACSF containing 1.5 mM NaOH and found that this concen-
tration NaOH, equivalent to that in local MCPG-containing
perfusate, had no effect on the amplitude of sEPSCs (96.3 	
4.6%, P  0.05, n 
 3, not shown).
Group II, but not I or III, mGluRs increase
sEPSC amplitude
To determine which of the subtypes of mGluRs are respon-
sible for the modulation of sEPSCs, we tested several mGluR
group-speciﬁc antagonists. The effect of MCPG was mimicked
by LY341495 (a group II antagonist), but HIBO and AIDA
(group I antagonists) decreased sEPSC amplitude and CPPG (a
group III antagonist) did not affect sEPSCs (Fig. 2). The effect
of the speciﬁc group II mGluR antagonist, LY341495 (2 M)
was larger and less variable than that of MCPG, in that it
increased sEPSC amplitude by an average of 42.0 	 10.3%
(P  0.05, n 
 11), as opposed to the mean 18% increase seen
in MCPG. Individual cumulative probability plots show that,
like MCPG, the change in amplitude in LY341495 was pre-
dominantly due to an increase in the number of large events
with very little effect on the small sEPSCs (Fig. 3Aii). The
effects of group I mGluR antagonists were examined in 14
neurons. AIDA (1mM) decreased sEPSC amplitude by 27.5 	
6.0% (P  0.05, n 
 9; representative cell in Fig. 2A, top) and
HIBO (200 M) reduced sEPSC amplitude by 28.7 	 11.8%
(P  0.05, n 
 5; P  0.05 AIDA vs. HIBO). The pooled data
of Fig. 2B show the effects of AIDA and HIBO on sEPSC
amplitude. Individual cumulative probability plots showed that
FIG. 2. Blockade of group II, but not group I or III
mGluRs increases sEPSC amplitude. A: graphs of sEPSC
amplitude vs. time for 3 cells, each exposed to an antagonist
of a different metabotropic glutamate receptor (mGluR)
group. After a 400-s pre-drug period, R()-1-amino-2,3-
dihydro-1H-indene-1,5-dicarboxylic acid (AIDA, group I; 1
mM), 2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-
(xanth-9-yl)propanoic acid (LY341495, group II; 2 M), and
(R,S)--cyclopropyl-4-phosphonophenylglycine (CPPG, group
III; 0.1 mM) were perfused for 400–5 0 0s( ), followed by
washout. ●, a single sEPSC. B: normalized mean sEPSC
amplitude for groups of neurons exposed to mGluR antago-
nists. MCPG increased amplitude of sEPSCs (n 
 15, P 
0.01); AIDA and (RS)-hexyl-HIBO (HIBO) decreased sEPSC
amplitude (n 
 14, results of 9 cells in AIDA and 5 cells in
HIBO pooled, P  0.001); LY341495 increased sEPSC am-
plitude (n
11, P0.01), while CPPG had no effect (-1.4 	
4.4%, n 
 7, P  0.05). For wash values, see text.
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predominantly due to a decrease in the number of large events
(Fig. 3Ai). Effects of MCPG, AIDA, and LY341495 were
reversible during the washout period (amplitude: MCPG
95.4 	 3.0%; AIDA 100.9 	 20.0%; and LY341495 103.2 	
4.6% of control levels following wash, P  0.05 for all). These
data suggest that the more modest effect of MCPG described in
the preceding text may have resulted from a simultaneous
increase of sEPSC amplitude due to antagonism of group II
mGluRs, together with a decrease via blockade of group I
mGluRs. The group III mGluR antagonist, CPPG (100 M),
was ineffective in changing amplitude or frequency of sEPSCs
(n 
 7, Figs. 2 and 3). These data indicate that mGluRs of
groups I and II are activated in unstimulated slices and have a
role in modulating sEPSCs.
Increase in sEPSCs is not due to disinhibition
of pyramidal neurons
It has been shown that fast-spiking (GABAergic) cells can
be depolarized and generate rhythmic activity when exposed to
mGluR agonists (Boddeke et al. 1997; McBain et al. 1994;
Whittington et al. 1995). Thus inactivation of mGluRs might
result in hyperpolarization of these neurons, a reduction in their
activity, and a secondary increase in the activity of downstream
pyramidal cells. If the effects of mGluR antagonists on sEPSCs
in pyramidal cells are indirect, i.e., due to disinhibition, the
actions of these agents should be occluded by GABAA and
GABAB antagonists. In the presence of the GABAA receptor
antagonist gabazine (8 M), which should block both phasic
and tonic GABAA receptor-mediated inhibition (Stell and
Mody 2002), LY341495 (2 M) produced a signiﬁcant (P 
0.05) increase in sEPSC amplitude in eight of eight cells (Fig.
4). This response was generally similar to that seen with
perfusion of LY341495 alone (cf. Figs. 2A and 4B) with the
exception that spontaneous bursts of EPSCs occasionally oc-
curred, probably representing spontaneous epileptiform events
(e.g., Fig. 4B, 900 s). A similar signiﬁcant effect of
LY341495 was seen in seven of eight cells exposed to the
GABAB receptor antagonist CGP 55845 (0.2–1 M) (Blake et
al. 1993). Therefore it is unlikely that mGluR actions on
GABAergic cells are necessary for the observed increase in
sEPSC amplitude.
Changes in sEPSC amplitude do not occur in
TTX-containing solutions
Because mean action potential-dependent EPSCs may be
larger in amplitude than miniature EPSCs (Berretta and Jones
1996), a change in presynaptic ﬁring could account for the
above effects of LY341495 and AIDA. When TTX (1–3 M)
was included in the bathing medium to block action potentials,
neither MCPG (n 
 7), AIDA (n 
 6), nor LY341495 (n 
 6)
induced a change in sEPSC amplitudes (P  0.05, Fig. 4A).
Furthermore, in four cells where MCPG elicited an average
increase in sEPSC amplitude of 31.1 	 16.4%, TTX treatment
during the MCPG exposure reduced the sEPSCs by 25.8 	
8.8% (P  0.05). Therefore the changes in the number of large
events seen after block of group I or II mGluRs likely result
from action-potential-evoked EPSCs. These data suggest that
spike ﬁring in at least some spontaneously active cells is
apparently modiﬁed under resting conditions by activation of
group I and II mGluRs.
Holding current and membrane potential are changed
by mGluRs
Application of group I and II mGluR agonists and antago-
nists elicited reversible shifts in holding currents in layer V
pyramidal cells. AIDA, a group I antagonist, shifted holding
FIG. 3. Antagonism of group I or II mGluRs changes the frequency of
large-amplitude sEPSCs. A: cumulative probability plot of sEPSC amplitudes
from 3 neurons. Compared with the control conditions, there were fewer large
(25 pA) sEPSCs in the presence of HIBO (i), more large sEPSCs in the
presence of LY341495 (ii), and no signiﬁcant change in the number of large
sEPSCs in the presence of CPPG (iii). Light lines: drug application; dark lines:
control. B: graph showing the change in frequency of sEPSCs 25 pA in
AIDA/HIBO (pooled data), LY341495, and CPPG. Probability values: **, P 
0.01; ***, P  0.001; ns, P  0.05.
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5Aii), indicating a negative or hyperpolarizing shift in Vm. The
reversal potential for the shift, obtained from injection of
voltage ramps, was 71 	 6m V( n 
 4). A group I agonist,
DHPG (100 M), elicited an average 126-pA negative shift in
holding current (Fig. 5Ai). In contrast to AIDA, the group II
antagonist, LY341495, caused an average 28-pA negative shift
of holding current (Fig. 5Bii). The group II agonist, DCG IV (1
M) shifted the holding current by an average 209 pA in the
positive direction (Fig. 5Bi). To determine whether the shifts in
holding current elicited by LY341495 or by AIDA were de-
pendent on impulse-related spontaneous synaptic activity, each
antagonist was applied to six cells from slices bathed in TTX-
containing perfusate. Under these conditions, AIDA elicited a
positive shift (56 	 24 pA, n 
 6) and LY341495 elicited a
negative shift in holding current (110 	 33 pA, n 
 6). These
results suggest that blockade of group I and II mGluRs directly
changes membrane potential (Vm), independent of an effect on
impulse-related transmitter release. The reversal potential of
the LY341495-induced current was 76 	 4m V( n 
 4).
To further test the hypothesis that endogenous activation of
group II mGluRs directly affects cellular excitability, current-
clamp recordings were obtained from six cells with resting
Vms between 57 and 61 mV, during LY341495 applica-
tion. LY341495 (2 M) reversibly depolarized Vm by 1–4m V
(6 of 6 cells; average 2.3 	 1.2 mV, P  0.01; Fig. 6, A and
C). In each cell, depolarizing current pulses evoked more
spikes during LY341495 application than in control solution
(Fig. 6, A and B). The occurrence of action potentials in 8-s
intervals between current pulses was analyzed. LY341495 ap-
FIG. 4. Changes in sEPSC amplitude elicited by mGluR antagonists require action potential generation, but not involvement of
GABAergic cells. A: graph showing the effect of LY341495 (2 M), MCPG (100–200 M), or AIDA (1 mM) on sEPSC amplitude
under several conditions. The enhancement of sEPSC amplitude by LY341495 was not affected by concomitant exposure of slices
to antagonists for either GABAA (gabazine, 8 M, n 
 8), or GABAB receptors (CGP55845, 0.2–1 M, n 
 8). LY341495,
MCPG, or AIDA perfusion had no signiﬁcant effect on sEPSCs in the presence of 1–2 M TTX (LY341495: n 
 6; MCPG: n 

7; AIDA: n 
 6). *, a signiﬁcant increase in sEPSC amplitude compared with control (P  0.05). The effects of LY341495 alone
on sEPSC amplitude were not signiﬁcantly different from those obtained in gabazine or CGP55845. LY, LY341495; MC, MCPG;
AI, AIDA; Gab, gabazine; CGP, CGP55845. B: graphs of sEPSC amplitude vs. time for 2 cells included in the bar graph of A. Top:
cell was exposed to gabazine (8 M) for 15 min before application of LY341495 (2 M). Note, the burst of EPSCs at 900 s,
is likely due to a spontaneous epileptiform event. Bottom: cell exposed to TTX (2 M), followed by MCPG (0.2 mM) 1,500s
later. ●, a single sEPSC.
FIG. 5. Group I and II mGluRs have opposite effects on holding current. A:
group I drugs. Ai: agonist (S)-3,5-dihydroxyphenylglycine (DHPG, 100 M,
n 
 5) shifts holding current in the negative direction. Aii: antagonist AIDA (1
mM, n 
 5) shifts holding current in the positive direction. B: group II drugs.
Bi: agonist DCG IV (1 M, n 
 7) shifts holding current in the positive
direction. Bii: antagonist LY341495 (2 M, n 
 8) shifts holding current in the
negative direction. All holding current measurements in A and B were made
relative to pre-drug holding current.
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TTX data of Fig. 4 suggest that these changes in excitability
likely resulted in alterations in the frequency of spontaneous
action potentials.
DISCUSSION
Our results show that antagonists of group I and II, but not
group III, mGluRs alter cellular excitability and impulse-re-
lated EPSCs in layer V pyramidal neurons of neocortical slices.
These ﬁndings suggest that the low concentrations of ambient
glutamate known to be present in brain slices (see references in
INTRODUCTION) are sufﬁcient to activate these receptors. Judging
from effects of antagonists, activation of group II mGluRs
reduces excitability, whereas activation of group I mGluRs
increases excitability. The effects of mGluR antagonists persist
in GABAA or GABAB receptor blockers and are therefore not
due to indirect actions resulting from disinhibition. These
ﬁndings support the conclusion that spontaneous ﬁring of layer
V neurons is enhanced and suppressed by activated group I and
II mGluRs, respectively.
The ﬁnding that group I mGluRs increase and group II
mGluRs decrease excitability, when activated, is not entirely
consistent with previous results obtained with application of
exogenous mGluR agonists (for review see Anwyl 1999; Boc-
kaert and Pin 1999; Schoepp 2001). For example, it has been
previously reported that the group II agonist DCG IV does not
affect membrane potential in layer V cells (Cho et al. 2000;
Otani et al. 2002). Yet in our experiments, DCG IV and
LY341495 had opposite effects on holding current, indicating
that activation of group II mGluRs decreases cellular excitabil-
ity. However, our data do agree with those of previous studies
showing that DHPG produces a negative-going shift in holding
current (for review see Wisniewski and Carr 2002), and we
show that opposite effects are produced by antagonists of
group I mGluRs, suggesting that group I mGluRs are activated
in brain slices in the absence of overt stimulation. Our data
support the conclusion that group I and II, but not III, mGluRs
can directly alter membrane excitability and also affect release
of glutamate in unstimulated slices through modulation of
pyramidal cell spike frequency.
The reduction of sEPSCs is most likely to be a group-I-
mediated effect. The reduction can be seen with both AIDA (1
mM) and HIBO (0.2 mM), molecules with different chemical
structures that both antagonize group I mGluRs, ruling out
some of the arguments for nonspeciﬁc effects of either drug.
Furthermore, the effects of a group I mGluR agonist (DHPG),
are opposite to the effects of AIDA, at least on the holding
current, adding credibility to the claim that AIDA is acting as
a group I antagonist. Additionally, the decrease does not appear
to be an artifact of the drug application process, as sEPSCs are
increased by group II antagonists and unchanged by NaOH
application. Finally, the concentration of AIDA used, 1 mM,
should affect both subtypes of group I mGluRs as this was
reported to be the EC50 for mGluR5 (EC50 for mGluR1 is 0.2
mM) (see Pellicciari et al. 1995).
LY341495 is not a selective group II mGluR antagonist
when used at higher concentrations (see Fitzjohn et al. 1998;
Kingston et al. 1998; Ornstein et al. 1998; Schaffhauser et al.
1998); however, the concentration used in this study (2 M)
likely only affects group II mGluRs. Several lines of evidence
suggest a speciﬁc role for group II mGluRs in the LY341495-
mediated response. First, the increase in sEPSCs was also
found for MCPG, a compound most active at group II and I
mGluRs and almost inactive at group III sites (Jane et al. 1993;
Pellicciari et al. 2001), indicating that the increase is not an
effect of group III mGluRs. Second, group I mGluR antago-
nists AIDA (Moroni et al. 1997) and HIBO (Madsen et al.
2001) reduce, rather than enhance, sEPSC amplitudes, suggest-
ing that the increase is not group I mediated. Third, the group
III antagonist, CPPG (Jane et al. 1996), had no effect on
sEPSCs, again suggesting that the increase is not group III
mediated. Therefore the increase in sEPSCs is mediated via
group II mGluRs, and the decrease is group I mediated. Be-
cause group I and II, but not group III, mGluRs have been
found in extrasynaptic locations, it has been concluded that
group I and II mGluRs are activated under conditions of lateral
diffusion of glutamate or “spillover” (for review, see Anwyl
1999). It is possible that these receptors are activated in the
presence of high-frequency neuronal activity that increases the
ambient level of glutamate; however, the present results sug-
gest that these receptors are also activated under resting con-
ditions in brain slices.
FIG. 6. A group II mGluR antagonist increases excitability
of layer V pyramidal cells. A: LY341495 increases numbers of
action potentials evoked by depolarizing current pulses. Cur-
rent-clamp recording of responses to increasingly intense de-
polarizing current pulses before (darker trace, control) and
after local perfusion of LY341495 (lighter trace). Vm: 61
mV in control and –59 mV after LY341495. Spikes are
truncated. Spike height: 64 mV. B: graph of the average
number of spikes evoked by current pulses with amplitudes
shown in A. Data show means for 6 cells under control
(Pre-Drug) and LY341495 conditions. Fifteen to 20 consecu-
tive responses were used to generate the average for each cell,
in each condition. *, P  0.05, Pre-Drug vs. LY341495. C:
graph of the membrane potential before, during, and after local
perfusion of LY341495 (2 M; n 
 6; horizontal bar).
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to changes in spike frequency of cells within the neocortex.
This conclusion is based on data showing that mGluR-medi-
ated changes in the frequency of large-amplitude sEPSCs are
absent in TTX. Previous reports show that TTX-insensitive
miniature EPSCs (mEPSCs) are decreased in frequency by
agonists of group II mGluRs in several preparations (Scanziani
et al. 1995; Schoppa and Westbrook 1997; Tyler and Lovinger
1995), suggesting that group II mGluR antagonists should
affect mEPSCs. However, mEPSCs are not signiﬁcantly af-
fected by LY341495 in our experiments, making it unlikely
that mGluRs on the axon terminal are activated by endogenous
glutamate in slices. Another possible interpretation of this
result is that TTX reduces the concentration of ambient gluta-
mate present in slices, resulting in a lower occupation of
receptors and a decrease in the effects of both AIDA and
LY341495. However, our data also show that AIDA and
LY341495 continue to have an effect on the holding current of
cells in the presence of TTX even though the effect of these
drugs on sEPSCs is eliminated. Therefore it is unlikely that
reduced ambient glutamate concentration in TTX accounts for
the effect of these antagonists on large sEPSCs. The source of
the excitatory synaptic events that are affected by mGluR
antagonists is not clear from our results, although current-
clamp recordings reveal that layer V cells, known to innervate
neighboring pyramidal neurons (Gilbert 1985; Kisvarday et al.
1986; Lubke et al. 1996; Markram et al. 1997; Schwark and
Jones 1989; for review see Markram 1997) did ﬁre more action
potentials in the presence of LY341495. It has not been deter-
mined if cells in other layers of the cortex or other brain
regions are similarly affected by group I and II mGluR antag-
onists.
The nature of the conductance underlying the shift in mem-
brane potential remains unexplored. The reversal potential of
this current, about 70 mV, is not near EK or ECl, calculated
to be 95 and 57 mV, respectively, in our experiments. This
indicates that more than one conductance is activated by am-
bient glutamate as has been proposed for mGluR1 actions in
CA1 cells (Crepel et al. 1994). The conductance activated by
ambient glutamate would increase the electrotonic length of the
recorded pyramidal neurons, and blockade of the resting con-
ductance would be associated with a decreased electrotonic
length and an improved space clamp. The resultant improved
voltage-clamp ﬁdelity would be expected to increase the am-
plitude of all distal synaptic events. However, we observed a
speciﬁc increase in the frequency of large events, suggesting
that altered voltage-clamp conditions cannot explain our re-
sults.
In a recent review, it was suggested that group II presynaptic
mGluRs may be partially occupied (activated) at rest because
these receptors are sensitive to glutamate in the micromolar
range, and extracellular levels of glutamate readily reach these
concentrations (Schoepp 2001). The present observations tend
to support this conclusion because neither MCPG nor
LY341495 should have any effect without some level of acti-
vation of mGluRs by an endogenous agonist in unstimulated
slices. Furthermore, the ﬁndings that HIBO and AIDA de-
crease sEPSC amplitude and shift holding current suggest that
group I mGluRs are also at least partially occupied at rest,
whereas group III are not. Another possibility, at least for
group I mGluRs, is that they may be constitutively active in the
absence of glutamate, as was suggested by Ango and col-
leagues (2000). This constitutive activity may account for a
portion of the present data obtained with antagonists; however,
it is unlikely that constitutive activity accounts for a large
portion of the effect as there is very little activity in wild-type
cells containing Homer1a protein (Ango et al. 2000). The
above-described effects of mGluRs should be greatly exagger-
ated in the intact brain as the levels of spontaneous activity,
and therefore the extracellular concentration of glutamate,
should be much higher (e.g., Pare et al. 1998; Steriade 2001).
Therefore we believe that our results may underestimate the
importance of mGluRs in the tonic control of excitability
within cortical circuits.
Ambient levels of glutamate (0.5–2 M) can also affect
NMDA receptors that are sensitive to glutamate concentrations
in the range of 2.5–3 M (Meldrum 2000). Indeed, an APV-
sensitive steady-state inward current can be observed in corti-
cal neurons if Mg
2 is left out of the bathing medium (see
Blanton et al. 1990; LoTurco et al. 1990), suggesting that
extracellular levels of glutamate in brain slices are high enough
to activate NMDA receptors under some circumstances. Low
levels of glutamate may be critical in early stages of cortical
development for activation of NMDA receptors present in
embryonic cortical cells that have migrated away from the
ventricular zone into the cortical plate (Blanton et al. 1990;
LoTurco et al. 1991). These receptors are present before the
emergence of synapses, suggesting that they may guide devel-
opment of the immature neuron and be dependent on ambient
levels of glutamate for their activation. mGluRs may also have
an important developmental role during synaptogenesis as ev-
idenced by changes in mGluR expression that accompany
differentiation of cortical laminae (Furuta and Martin 1999;
Mun ˜oz et al. 1999). Also, mGluR expression patterns in visual
cortex are altered during development and can be delayed by
dark rearing (Reid et al. 1997). Many behavioral manifesta-
tions of brain function, such as alertness, sleep, and affective
states, are best described as tonic in their time course. A variety
of data from studies of glutamatergic (Blanton et al. 1990;
LoTurco et al. 1990; present results) GABAergic (Hamann et
al. 2002; Salin and Prince 1996) and perhaps other types of
neurotransmission in the brain (Bunin and Wightman 1999)
suggest that ongoing tonic extrasynaptic receptor activation is
ubiquitous, raising the interesting hypothesis that ongoing
tonic receptor activation has important functional behavioral
consequences.
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